Anti-CD3 x Anti-B7H3 Bispecific Antibody (IgG-IgG) (BSIG-064)

Anti-CD3 x Anti-B7H3 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD3 and anti-B7H3 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & B7H3

Type

IgG-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Solid tumors

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

B7H3

Gene ID

80381

UniProt ID

Q5ZPR3

Alternative Names

B7H3; B7 homolog 3; CD276; CD276 molecule; B7-H3; B7RP-2; 4Ig-B7-H3; B7-related protein 2; B7RP2; B7 homologue 3

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD3 x Anti-B7H3 Bispecific Antibody (IgG-IgG) (BSIG-064). Click the button below to contact us or submit your feedback about this product.

Anti-CD3 x Anti-B7H3 Bispecific Antibody (IgG-IgG) (CAT#: BSIG-064)

Specifications

Targets

Customer Reviews and Q&As